Key Takeaways
- 4D Molecular Therapeutics awarded 66,900 Restricted Stock Units (RSUs) to seven new non-executive employees.
- The RSUs were granted under the company’s 2025 Employment Inducement Award Plan to attract talent.
- 4DMT is advancing therapies for retinal diseases, including wet age-related macular degeneration and cystic fibrosis.
Company Updates and Product Candidates
4D Molecular Therapeutics (Nasdaq: FDMT) announced on June 9, 2026, the grant of 66,900 Restricted Stock Units (RSUs) to seven new non-executive employees. This initiative follows the company’s 2025 Employment Inducement Award Plan, aimed at attracting skilled professionals to bolster its workforce.
4D Molecular Therapeutics is a prominent late-stage biotechnology firm focused on developing durable and targeted therapies with the potential to revolutionize treatment approaches, significantly enhancing patient outcomes. The company’s lead product candidate, 4D-150, is positioned as a foundational therapy for treating blinding retinal vascular diseases. This innovative treatment offers multi-year sustained delivery of anti-VEGF agents (aflibercept and anti-VEGF-C) through a single, safe intravitreal injection, addressing the treatment challenges linked to current methods.
Currently, 4D-150 is in Phase 3 clinical development for its primary indication of wet age-related macular degeneration, with a secondary focus on diabetic macular edema. The company is also advancing its second product candidate, 4D-710, which is notable as the first genetic medicine successfully demonstrating the delivery and expression of the CFTR transgene in the lungs following aerosol delivery, targeting cystic fibrosis.
As the company’s initiatives progress, all product candidates remain in clinical or preclinical stages and await approval from the U.S. Food and Drug Administration and other regulatory bodies. No representations regarding the safety or effectiveness of these candidates for their intended therapeutic uses have been made.
For additional information, 4DMT’s official website and LinkedIn page provide updates on its ongoing projects and advancements in biotechnology.
The content above is a summary. For more details, see the source article.